To Identify Urinary Biomarkers Associated With Gestational Diabetes Mellitus [GDM]

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05992974
Collaborator
Mudanjiang First People's Hospital (Other), Mudanjiang Maternal and Child Health Hospital (Other)
1,000
1
28
35.7

Study Details

Study Description

Brief Summary

Gestational diabetes mellitus(GDM) is one of the most common complications of pregnancy. The incidence of GDM is higher in Asian than in other regions, and GDM can increase the risk of a series of perinatal complications. The investigators has been committed to the early diagnosis of GDM, and several biomarkers in the first trimester and urinary proteomic markers that were associated with GDM have been found. Based on the previous work, the aim of this study was to verify the predictive ability of urinary proteomic markers for GDM that has been found in the previous study of the researchers. This study is a multi-center, prospective, and observational study. Urine samples will be collected twice, at 12 weeks and 24-28 weeks of gestation, respectively.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The eligibility criteria are as follows:
    1. singleton pregnant women over 18 years old;

    2. gestational age less than 12 weeks;

    3. regular follow-up until delivery;

    4. able to understand and sign an informed consent.

    The exclusion criteria of pregnant women are as follows:
    1. with impaired glucose tolerance or diabetes mellitus before pregnancy;

    2. severe chronic diseases or infectious diseases (e.g., liver disease, urinary system disease, cardiovascular disease, autoimmune disease, hematological disease, AIDS and other diseases before pregnancy);

    3. medications other than vitamins used during pregnancy;

    4. inability to understand and follow-up regularly;

    5. other conditions judged by the investigators to be inappropriate for participation in the study.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    To Identify Urinary Biomarkers in the First Trimester Associated With Gestational Diabetes Mellitus [GDM] and Achieve Early Diagnosis of GDM Using Urinary Proteomic Analysis: An Observational Study
    Anticipated Study Start Date :
    Aug 1, 2023
    Anticipated Primary Completion Date :
    Dec 1, 2025
    Anticipated Study Completion Date :
    Dec 1, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Number of participants with gestational diabetes [at 24-28 weeks of gestation]

      Diagnosed by 75g-OGTT at 24-28 weeks of gestation. GDM was diagnosed according to the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criterion in 2010: fasting blood glucose ≥5.1mmol/L, and/or 1-hour blood glucose ≥10.0mmol/L, and/or 2-hour blood glucose ≥8.5mmol/L

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    • Women of childbearing age who are in early pregnancy(gestational age less than 12 weeks);

    • Regular prenatal examination until delivery;

    • Older than 18 years old;

    • Obtained informed consent from participants and/or their family members.

    Exclusion Criteria:
    • Twins or multiple pregnancy;

    • With impaired glucose tolerance or diabetes mellitus before pregnancy;

    • With severe chronic diseases or infectious diseases (e.g., liver disease, urinary system disease, cardiovascular disease, autoimmune disease, hematological disease, AIDS and other diseases before pregnancy);

    • Medications other than vitamins used during pregnancy;

    • Inability to understand and follow-up regularly;

    • Other conditions that were judged by the investigator to be ineligible for participation in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mudanjiang First People's Hospital Mudanjiang Heilongjiang China

    Sponsors and Collaborators

    • Peking Union Medical College Hospital
    • Mudanjiang First People's Hospital
    • Mudanjiang Maternal and Child Health Hospital

    Investigators

    • Principal Investigator: Tedros Adhanom Ghebreyesus, World Health Organization

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Peking Union Medical College Hospital
    ClinicalTrials.gov Identifier:
    NCT05992974
    Other Study ID Numbers:
    • 202303075GDM
    • K4087
    First Posted:
    Aug 15, 2023
    Last Update Posted:
    Aug 18, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Peking Union Medical College Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 18, 2023